Hepion Pharmaceuticals Bolsa (NASDAQ: HEPA)

Últimas noticias sobre Hepion Pharmaceuticals (NASDAQ:HEPA) Bolsa

Hepion Pharmaceuticals

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals Inc

Barrington Research analyst Gary Prestopino maintains Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) with a Outperform and maintains $110 price target.

News

Price Target

Analyst Ratings

DAVE

Barrington Research Maintains Outperform on Dave, Maintains $110 Price Target

Shares of Target Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) are trading lower in <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">premarket on Tuesday</a> after the fourth-quarter FY24 earnings.
The company reported a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44103957/target-corporation-reports-fourth-quarter-and-full-year-2024-earnings" rel="noreferrer noopener">fourth-quarter sales decline </a>of 3.1% year-on-year to $30.91 billion, beating the analyst consensus estimate of $30.84 billion.
Comparable sales increased 1.5% in the fourth quarter, reflecting strong traffic and digital performance. Digital comparable sales grew 8.7%.
Adjusted EPS of $2.41 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the consensus</a> estimate of $2.26.
Gross margin for the quarter contracted by 40 basis points to 26.2%, reflecting higher digital fulfillment and supply chain costs and higher promotional and clearance markdown rates.
Operating&nbsp;income margin rate of 4.7% was 110 basis points lower than last year, and the&nbsp;operating income for the quarter plunged 21.3% to $1.47 billion.
The&nbsp;company held $4.7 billion in cash and equivalents&nbsp;as of February 1.&nbsp;Operating cash flow for twelve months totaled $7.4 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/25/03/44081963/ford-february-us-sales-slide-8-9-ev-sales-jump-15-details" rel="noreferrer noopener">Ford February US Sales Slide 8.9%, EV Sales Jump 15%: Details</a>
Inventory as of February was $12.74 billion, compared to $11.8 billion last year. The company paid dividends of $513 million in the fourth quarter, compared with $508 million last year.
As of the end of the fourth quarter, TGT had approximately&nbsp;$8.7 billion&nbsp;of remaining capacity under the repurchase program approved by the Board of Directors in&nbsp;August 2021.
&#8220;Our team grew traffic and delivered better-than-expected sales and profitability in our biggest quarter of the year,&#8221;&nbsp;said chair and chief executive officer Brian Cornell.
&#8220;Results were led by strong performance in Beauty, Apparel, Entertainment, Sporting Goods and Toys. As we look ahead, our continued investments in digital capabilities, stores and supply chain—combined with a focus on newness, value, speed and reliability—will further differentiate our one-of-a-kind physical and digital shopping experience.&#8221;
Outlook: Target expects FY25 adjusted EPS of $8.80 – $9.80 versus an estimate of $9.31. It sees comparable sales to be flat. The company sees FY25 sales growth <a href="https://www.benzinga.com/calendars/guidance">to be around 1%.</a>
Due to continued consumer uncertainty, a slight drop in February net sales, tariff instability, and the anticipated timing of certain expenses throughout the fiscal year, the company expects to face significant year-over-year profit challenges in the first quarter compared to the rest of the year.
&#8220;During February, we saw record performance around Valentines Day. However, our topline performance for the month was soft, as uncharacteristically cold weather across the U.S. affected apparel sales, and declining consumer confidence impacted our discretionary assortment overall,&#8221; said&nbsp;Jim Lee, chief financial officer.
Price Action: TGT shares traded lower by 1.88% at $118.49 in premarket at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44074819/servicenow-unveils-ai-agents-for-telecoms-in-collaboration-with-nvidia" target="_blank" rel="noreferrer noopener">ServiceNow Unveils AI Agents For Telecoms In Collaboration With Nvidia</a></li>
</ul>
Photo via Shutterstock.

Earnings

Equities

Large Cap

Guidance

Movers

General

Target CEO Cautions Tariffs Will Pressure FY25 Profit, Consumer Uncertainty To Hit Feb Sales

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) with a Buy and maintains $16 price target.

Reiteration

CALC

HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $16 Price Target

Biotech

HOTH

Hoth Therapeutics Announces Preclinical Findings On Potential Of Glial Cell Line-Derived Neurotrophic Factor; Says Findings Include Protection Against High-Fat Diet-Induced Obesity, Enhanced Fat Burning and Energy Expenditure, Adipogenesis, Improved Insulin Sensitivity and Glucose Regulation And Reduced Fatty Liver Disease

Mizuho analyst Gregg Moskowitz maintains GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) with a Outperform and lowers the price target from $80 to $72.

GTLB

Mizuho Maintains Outperform on GitLab, Lowers Price Target to $72

Telsey Advisory Group analyst Cristina Fernandez maintains On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Outperform and maintains $67 price target.

ONON

Telsey Advisory Group Maintains Outperform on On Holding, Maintains $67 Price Target

Barclays analyst Ramsey El-Assal downgrades AvidXchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>) from Overweight to Equal-Weight and lowers the price target from $13 to $8.

Downgrades

AVDX

Barclays Downgrades AvidXchange Holdings to Equal-Weight, Lowers Price Target to $8

On Tuesday, BioHarvest Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHST#NASDAQ">BHST</a>) published ‘in vitro' test results for its new olive cell compound, which can reduce fat accumulation in human liver cells.
BioHarvest demonstrated that its novel olive cell compound mitigated fat accumulation in human liver cells, both in a liver steatosis model and in experimental liver fibrosis models.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/12/42431837/exclusive-bioharvest-collaborate-with-tate-lyle-to-develop-proprietary-plant-based-molecules" rel="noreferrer noopener">EXCLUSIVE: BioHarvest Collaborates With Tate &amp; Lyle To Develop Proprietary Plant-Based Molecules</a>
The company attributes the reduction of fat accumulation in liver cells to the high levels of Verbascoside (a plant-derived polyphenol with known anti-inflammatory properties that has been researched for various effects on the liver) in BioHarvest's Olive cell compound.
Based on these results and additional studies to be conducted in 2025, the company expects to begin selling the Olive Cell product in 2026 as a nutraceutical product while continuing to explore the potential of partnering with a pharmaceutical company to provide the olive cell composition via a different regulatory path as part of its contract development and production organization (CDMO) model.
The Olive product will join VINIA as part of the company's portfolio. VINIA, a grape cell product that is high in Piceid Resveratrol, has been clinically shown to significantly dilate arteries, resulting in increased blood flow.
The company recently announced that VINIA had surpassed $50 million in sales, with over 50,000 active subscribers.
BioHarvest plans to support future growth by expanding its production capacity by 4x and building a new 100-ton-per-year production facility, which is expected to be <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/43780365/bioharvest-announces-sales-of-flagship-product-vinia-now-exceed-50-million-usd" rel="noreferrer noopener">operational in late 2026</a>.
Price Action: BHST stock closed at $5.03 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/03/44103926/grocery-giant-albertsons-names-susan-morris-as-new-ceo" target="_blank" rel="noreferrer noopener">Grocery Giant Albertsons Names Susan Morris As New CEO</a></li>
</ul>

Health Care

Market-Moving Exclusives

Exclusives

BHST

EXCLUSIVE: Botanical Synthesis Tech-Focused BioHarvest's First Synthetic Olive Cells Shows Reduced Fat Accumulation in Liver Cells

<a href="https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions" title="https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions">https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions</a>

Johnson & Johnson MedTech Says 'Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform In U.S. To Transform Treatment Of Difficult-To-Cross Calcified Lesions'

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

MARA

MARA Holdings February Bitcoin Product 706 Down From 750 MoM

EXCLUSIVE: BioHarvest Tells Benzinga 'In Vitro Testing of First Lab-Grown Plant-Based Molecules Proves Reduced Fat Accumulation in Liver Cells'

EXCLUSIVE: BioHarvest Tells Benzinga Co. Shows First Synthetic Olive Cells A Capable New Weapon In Fight Against Liver Disease

Parent Company Discusses Strategy to Evolve into a Broader Holding Company with a Focus on Emerging Technologies
NEW YORK, March 4, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/DOMH#NASDAQ">DOMH</a>)&nbsp;(the "Company") today announced that its wholly-owned subsidiary, Dominari Securities LLC ("Dominari"),&nbsp;has received approval for its Continuing Membership Application ("CMA") from the Financial Industry Regulatory Authority ("FINRA"). The Company also provided additional commentary regarding its plans to develop into a broader holding company with a focus on emerging technologies.

DOMH

Dominari Securities Receives FINRA Approval For Its CMA To Expand Operations

WIIM

BeiGene shares are trading higher after the company announced FDA approval of Tevimbra/chemotherapy combination.

On March 3, 2025, iCoreConnect, Inc. (the "Company") entered into warrant cancellation agreements with the holders of warrant to purchase an aggregate of 142,690 shares of common stock. The canceled warrants included anti-dilution provisions that could have led to an increase in the number of warrants and a reduction in the exercise price if new shares were issued by the Company at a lower price.
 &nbsp;

ICCT

iCoreConnect On Mar. 3 Entered Into Warrant Cancellation Agreements With The Holders Of Warrant To Purchase An Aggregate Of 142,690 Shares Of Common Stock

&nbsp;
Tiziana Life Sciences, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) (&quot;Tiziana&quot; or the &quot;Company&quot;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the submission of its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 2 clinical trial in ALS. This pivotal step marks a significant advancement in the company&#39;s commitment to advance a new treatment approach for Amyotrophic Lateral Sclerosis (ALS) which is supported by the ALS Association.
This IND filing follows the prestigious award of a grant as part of the Hoffman ALS Clinical Trial Awards Program from the ALS Association. Tiziana&#39;s intranasal foralumab development programs are now focused on 3 neurodegenerative diseases. ALS, Multiple Sclerosis, and Alzheimer&#39;s disease. This grant provides a framework for industry-academia collaboration where new discoveries are translated to clinical studies through innovative research and development.
ALS, also known as Lou Gehrig&#39;s disease is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord, ultimately leading to muscle weakness and paralysis. ALS is an orphan disease, but its clinical course can be rapid with marked disability even at an early stage. Over the course of the disease, people lose the ability to move, to speak, and eventually, to breathe. The disease is always fatal, usually within five years of diagnosis. Despite its devastating impact, treatment options remain limited, highlighting the critical importance of advancing research efforts like those undertaken by Tiziana Life Sciences.

TLSA

Tiziana Life Sciences Announces Investigational New Drug Application Submission For Phase 2 Trial Of Intranasal Foralumab In ALS

- STAR-1 topline results expected by the end of March 2025 -
- Over 30 million acne patients seek treatment in the U.S. each year -
- XYNGARI&#x2122; Phase 3 STAR-1 trial enrolled 520 patients with moderate-to-severe acne in the U.S.&nbsp; and Latin America -

DRMA

Dermata Announced Last Patient Completed Last Visit In XYNGARI Phase 3 STAR-1 Clinical Trial For Acne

New controlled study published in&nbsp;Journal of Nutrition and Dietary Supplements highlights statistically significant reductions in ethanol levels following acute alcohol intake
SCOTTSDALE, Ariz., March 04, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) ("Safety Shot" or the "Company"), a wellness and dietary supplement company, today announces the peer-reviewed publication of its groundbreaking randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy of Safety Shot&#xAE; in mitigating the negative effects of alcohol consumption. The study, published in the Journal of Nutrition and Dietary Supplements (Feb 26, 2025, Volume 17, Pages 43-62), demonstrates that Safety Shot&#xAE; statistically significantly reduces blood alcohol concentration (BAC), breath alcohol concentration (BrAC), and hangover symptoms compared to placebo (p &lt; 0.05), and at a remarkably faster rate than the body's natural processes. For the complete article, visit the website at: <a href="https://www.globenewswire.com/Tracker?data=WMrB5FCJ7spqdDFaiGgaOalIPHMLw7p7IOTyw0oAzKQ3WxqFYU0LFhPAP0b-gLXh5BNsAX0_KrPK6x9IyWGObFFPAF2q9v4zTdH-7dHHILiW1TDVIt0rcNZlwME-V15r">https://doi.org/10.2147/NDS.S507571</a>

SHOT

Safety Shot Announces First Peer-Reviewed Publication Of Human Clinical Trial Confirming Rapid Alcohol Reduction And Hangover Prevention Published In The Journal Of Nutrition And Dietary Supplements (Feb 26, 2025, Volume 17, Pages 43-62)

Mizuho analyst Vijay Rakesh maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Outperform and raises the price target from $58 to $68.

MCHP

Mizuho Maintains Outperform on Microchip Technology, Raises Price Target to $68

MASS

908 Devices shares are trading higher after the company reported Q4 financial results and beat its adjusted EPS and revenue estimates.

Press Releases

Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial

Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B

Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group

Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.

Hepion Pharmaceuticals Announces $9.0 Million Public Offering

Akanda

Artelo Biosciences

Avenue Therapeutics

Eyenovia

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharma

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

SenesTech

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TNF Pharmaceuticals

Universe Pharmaceuticals Inc - Ordinary Shares

Comments

Hepion Pharmaceuticals

Noticias

Últimas noticias sobre Hepion Pharmaceuticals (NASDAQ:HEPA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL